REG - RUA Life Sciences - Directorate Changes

Rua Life SciencesAnnouncement

31/03/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220331:nRSe6524Ga&default-theme=true

RNS Number : 6524G  RUA Life Sciences PLC  31 March 2022

 

 

 

 

 

 

31 March 2022

 

RUA Life Sciences Plc

("RUA Life Sciences", the "Company" or the "Group")

Directorate Changes

 

Further to its announcement of 16 December 2021, RUA Life Sciences, the
holding company of a group of medical device businesses focused on the
exploitation of the world's leading long-term implantable biostable polymer
(Elast-Eon(TM)), is pleased to announce the appointments, with immediate
effect, to the Board of Lachlan Smith as Chief Financial Officer, and Dr Iain
Anthony as Director of Clinical and Regulatory Affairs.

 

Iain joined the Company in November 2021 as Director of Clinical and
Regulatory Affairs and brings a wealth of relevant cardiovascular medical
device experience to the Company. He has over 15 years' experience in the
medical device industry in both commercial and NHS settings.  He was
recruited from the Swiss based MedAlliance where he was Director of
Pre-Clinical/Clinical Regulatory Affairs focusing on development and approval
of drug coated coronary and peripheral angioplasty balloons.  Prior to this,
Iain was Head of Clinical Affairs at Terumo Aortic where he developed his
knowledge and experience of the global vascular graft business.

 

Lachlan joined the Company in December 2021 as Chief Financial Officer and is
a Fellow of the Association of Chartered Certified Accountants. With 20 years'
experience in accounting and financial management and digital transformation,
the last 14 years of which were spent in strategic leadership roles at high
growth businesses. Prior to joining RUA Life Sciences, Lachlan served as
Finance Director at technology companies Silver Cloud Smarter Technology and
Equator.

 

Since their respective appointments, both Iain and Lachlan have been playing
key roles in the business providing the expertise to lead the revised
regulatory strategy and the detailed financial planning to maximise
contribution from the vascular graft range by prioritising both manufacturing
efforts and sales focus.

 

Further information in accordance with paragraph (g) of Schedule Two of the
AIM Rules for Companies is set out at the end of this announcement.

 

Caroline Stretton, Group Managing Director of the Company, commented: "The
Board appointments of Iain and Lachlan will ensure that we have the right
management expertise to support the growth of the Group and enable the
vascular graft business to accelerate its clinical study plans for earlier
entry into global markets."

 

Bill Brown, Chairman of the Company, commented: "I am delighted to be
welcoming two new members to our Board who bring with them a great deal of
knowledge and expertise and look forward to working with them in the coming
years."

 

For further information contact:

 

RUA Life Sciences

Bill Brown,
Chairman
     Tel: +44 (0)1294 317073

Caroline Stretton, Group Managing Director
    Tel: +44 (0)1294 317073

 

Shore Capital (Nominated Adviser and Joint Broker)   Tel: +44 (0)20 7408
4080

Tom Griffiths/David Coaten
 

 

Cenkos Securities plc (Joint
Broker)                             Tel: +44
(0)20 7397 8900

Max Gould (Corporate Finance)

Michael Johnson (Sales)

 

 

About RUA Life Sciences

 

The RUA Life Sciences group was created in April 2020 when RUA Life
Sciences Plc (formerly known as AorTech International Plc) acquired RUA
Medical Devices Limited to create a fully formed medical device business. RUA
Life Sciences is the holding company of the Group's four trading businesses,
each exploiting the Group's patented polymer technology.

 

Our vision is to improve the lives of millions of patients by enabling medical
devices with Elast-Eon(TM), the world's leading long-term implantable
polyurethane. Whether it is licensing Elast-Eon(TM), manufacturing a device or
component, or developing next generation medical devices, a RUA Life Sciences
business is pursuing our vision.

 

Elast-Eon™'s biostability is comparable to silicone while exhibiting
excellent mechanical, blood contacting and flex-fatigue properties. These
polymers can be processed using conventional thermoplastic extrusion and
moulding techniques. With over 8 million implants and 15 years of successful
clinical use, RUA's polymers are proven in long-term life enabling
applications.

 

The Group's four business units are:

 

 RUA Medical:           End-to-end contract developer and manufacturer of medical devices and
                        implantable fabric specialist.

 RUA Biomaterials:      Licensor of Elast-Eon(TM) polymers to the medical device industry.

 RUA Vascular:          Development of polymer sealed grafts and soft tissue patches.

 RUA Structural Heart:  Development of tri leaflet polymeric heart valves.

 

 INFORMATION REQUIRED UNDER SCHEDULE TWO, PARAGRAPH (G) OF THE AIM RULES FOR
 COMPANIES ("AIM RULES")

 Full name:                                                                      Lachlan Arthur Smith
 Age                                                                             41
 RUA Life Sciences plc ordinary shares held:                                     0
 Current directorships:                                                          Ornum Technology Limited
 Historic directorships (within previous 5 years):                               Baron Knight Limited
                                                                                 Laird Logistics Limited
                                                                                 Scottish Target Shooting
                                                                                 Silver Cloud Smarter Technology Limited

 Full name:                                                                      Iain Crawford Anthony
 Age                                                                             46
 RUA Life Sciences plc ordinary shares held:                                     0
 Current directorships and/or historic directorships (within previous 5 years):  None

 There is no further information to be disclosed in relation to the
 appointments of either Lachlan Smith or Iain Anthony pursuant to Schedule Two,
 paragraph (g) of the AIM Rules.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABUGDXXXXDGDG